---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Endoscopic ultrasound-guided ablation"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Endoscopic ultrasound-guided ablation. Topics: Radiofrequency ablation for small localized insulinoma: ENETS guidance, Nonsurgical ablation for localized insulinoma: clinical review, Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison, Prospective multicenter radiofrequency ablation including 30 insulinomas, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/endoscopic-ultrasound-guided-ablation"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Endoscopic ultrasound-guided ablation

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Endoscopic Ultrasound-guided Ablation

<a id="topic-2.2.2.1.2-1"></a>

### Radiofrequency ablation for small localized insulinoma: ENETS guidance

> “EUS-guided radiofrequency ablation (EUS-RFA) is a novel technique able to induce necrosis of small pancreatic lesions. EUS-RFA seems a safe and effective treatment option for small (≤2 cm) localised insulinomas, especially in patients considered unfit for surgery.”
> “In this regard, recent retrospective series and meta-analyses have shown a high clinical success rate (86%–96%), reporting only minor treatment-related adverse events”
> “However, further data in terms of long-term survival and recurrence rate are needed before proposing this procedure routinely in patients with small insulinomas, and these interventions should be confined to expert centres.”
> “EUS-RFA might be considered as treatment option in patients with small (≤2 cm) localised insulinomas considered as unfit for surgery [2a, C].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.2-2"></a>

### Nonsurgical ablation for localized insulinoma: clinical review

> “Nonsurgical therapy can be considered in patients who either have comorbidities precluding resection or do not want to undergo resection after being appropriately counseled about therapeutic options. In selected cases, curative EUS-guided radiofrequency ablation of a localized insulinoma can be feasible and safe, although long-term data are pending (19, 54, 103, 109–112).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.2-3"></a>

### Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison

> “Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis.”
> “Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160).”
> “However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients).”

Source: [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/)

<a id="topic-2.2.2.1.2-4"></a>

### Prospective multicenter radiofrequency ablation including 30 insulinomas

> “During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas”
> “Eight AEs occurred peri-procedurally, including five cases of mild acute pancreatitis all managed conservatively without prolongation of hospital stay or occurrence of any sequelae.”

Source: [Rizzatti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12550746/)

<a id="topic-2.2.2.1.2-5"></a>

### Ethanol and radiofrequency ablation of insulinoma: systematic review of published cases

> “In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session.”
> “The clinical success rate for EUS-guided ablation techniques was 98.5%.”
> “There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths.”

Source: [El Sayed et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8606734/)

<a id="topic-2.2.2.1.2-6"></a>

### Ethanol ablation versus surgery for insulinoma: single-center comparison

> “Of these, 9 patients were treated with EUS-guided ethanol injection and 24 underwent pancreatic surgery.”
> “The lowest glucose values were similar between groups before (ethanol: 2.09±0.17 mmol/l vs. surgery: 1.81±0.08, p=0.158) and after (4.95±0.74 vs. 5.41±0.28, p=0.581) the respective treatments. Complications occurred more frequently in the surgery group (11 % vs. 54 %, p=0.026). One patient after prior partial pancreatectomy died postoperatively. The hospitalization time was significantly shorter in the ethanol group (4.78±0.78 days vs. 19.88±4.07, p<0.001).”

Source: [Jürgensen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37931914/)

<a id="topic-2.2.2.1.2-7"></a>

### Ongoing randomized trial of radiofrequency ablation versus surgery for insulinoma

> “EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)”
> “The goal of this muticentre randomized controlled trial is to compare endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with surgery for treatment of pancreatic insulinoma.”
> “Patients will be randomized to undergo EUS-RFA or surgical resection.”

Source: [ClinicalTrials.gov NCT05735912](https://clinicaltrials.gov/study/NCT05735912)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
